Before these trials emerged, the PENELOPE-B trial was a randomized, double- blind, phase III trial that investigated the use of palbociclib (PAL) in HR+, HER2− breast cancer patients with residual disease after neoadjuvant chemotherapy who were at high risk of relapse [33]. This evidence concerns the gene ERBB2 and breast carcinoma.